On Friday, Amneal Prescription drugs Inc. AMRX reported fourth-quarter adjusted EPS of 12 cents, down from 14 cents a 12 months in the past and lacking the consensus of $0.15.
The corporate reported gross sales of $730.52 million, up 18% year-over-year, beating the consensus of $707.6 million.
The rise was pushed by Reasonably priced Medicines (beforehand Generics) revenues rising 21% resulting from new product launches, biosimilars, and a number of different complicated merchandise, AvKARE revenues rising 14% resulting from new product launches, and Specialty revenues rising 16% pushed by key branded merchandise together with CREXONT.
Additionally Learn: Generic Drug Maker Amneal Prescription drugs Is Positioned To Development Properly Forward Of Friends, Analyst Upgrades Inventory
It clocked a web lack of $31 million in comparison with a web lack of $99 million a 12 months in the past. Adjusted EBITDA within the fourth quarter of 2024 was $155 million, a rise of 9% in comparison with the fourth quarter of 2023, primarily resulting from sturdy income progress partially offset by greater spending in analysis and growth and industrial initiatives to drive future progress.
Steerage: Amneal expects 2025 revenues of $3 billion—$3.1 billion and adjusted EPS of $0.65-$0.70 versus the consensus of $2.9 billion and $0.71, respectively.
“In 2025 and past, we’re getting into a brand new part of progress by additional increasing in high-growth areas akin to Specialty, Biosimilars, and GLP-1 therapies. As a rising and diversified biopharmaceutical firm, Amneal is effectively positioned to ship substantial worth creation for all our stakeholders,” mentioned Chirag and Chintu Patel, Co-Chief Govt Officers.
The corporate expects 2025 adjusted EBITDA of $650 million—$675 million, working money move of $255 million—$285 million and capital expenditures of roughly $100 million.
Value Motion: On the time of this writing, Friday, AMRX inventory was up 1.43% at $8.50 through the premarket session.
Learn Subsequent:
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
